Micro
Aftermath
Archived
CAH กลายเป็นผู้มีส่วนร่วมหลักต่อความแข็งแกร่งของยา
กิจกรรมลดลง - เรื่องราวเริ่มไม่เกี่ยวข้อง
คะแนน
0.3
ความเร็ว
▲ 0.0
บทความ
10
แหล่งที่มา
2
ไทม์ไลน์ความรู้สึก
ผลการดำเนินงานรายกลุ่ม
ผลการดำเนินงานหุ้น
ไทม์ไลน์เหตุการณ์
เม.ย. 15, 2026
Evercore ISI Trims Cardinal Health (CAH) Target While Maintaining Bullish Rating
Bullish
บทความที่เกี่ยวข้อง
Jim Cramer Says Cardinal Health Is a “Steal”
Yahoo Finance
·
เม.ย. 28, 2026
What You Need to Know Ahead of Cencora's Earnings Release
Yahoo Finance
·
เม.ย. 18, 2026
We're adding to an out-of-favor stock with limited exposure to Iran war upheaval
CNBC
·
มี.ค. 25, 2026
Cardinal Health (CAH) Emerged as a Key Contributor on Pharmaceutical Strength and Margin Expansion
Yahoo Finance
·
มี.ค. 25, 2026
🤖
ภาพรวม AI
What happened: On March 23, Cardinal Health (CAH) appointed Patricia A. Hemingway Hall as Chair, succeeding Gregory B. Kenny. Jim Cramer's Charitable Trust increased its CAH stake to 475 shares, boosting its weighting to 2.6%. Renaissance Investment Management highlighted CAH's contribution to pharmaceutical strength and margin expansion in Q4 2025. Evercore ISI trimmed CAH's target price to $240 but maintained a bullish rating.
Market impact: CAH's board change and increased institutional interest signal confidence in the company's long-term prospects. Its positive performance in the pharmaceutical sector has driven investment in the drug and medical supplies distribution sector. The bullish sentiment is reflected in CAH's inclusion in dividend stock lists and its Outperform rating.
What to watch next: CAH's Q3 2026 earnings, scheduled for May 25, will provide insights into its ongoing performance. Additionally, any updates on the Iran situation could impact CAH's exposure to potential geopolitical risks. Lastly, monitor CAH's stock price around the $240 level, as it approaches Evercore ISI's revised target.
Market impact: CAH's board change and increased institutional interest signal confidence in the company's long-term prospects. Its positive performance in the pharmaceutical sector has driven investment in the drug and medical supplies distribution sector. The bullish sentiment is reflected in CAH's inclusion in dividend stock lists and its Outperform rating.
What to watch next: CAH's Q3 2026 earnings, scheduled for May 25, will provide insights into its ongoing performance. Additionally, any updates on the Iran situation could impact CAH's exposure to potential geopolitical risks. Lastly, monitor CAH's stock price around the $240 level, as it approaches Evercore ISI's revised target.
ภาพรวม AI ณ วันที่ พ.ค. 04, 2026
ไทม์ไลน์
พบครั้งแรกมี.ค. 25, 2026
อัปเดตล่าสุดมี.ค. 25, 2026